GOLDEN, CO / ACCESSWIRE / March 2, 2022 / Panacea Life Sciences, Inc. (OTCQB:PLSH), (the “Company”), a Colorado, USA-based biotech cannabinoid company, bolsters their skincare line with innovative CBD and CBG formulations to help combat skin issues like acne, wrinkles, and even more severe conditions such as eczema and psoriasis. These products, specifically the Skin Clearing Gel for acne and the Derma Soothe CBD+CBG oil for more severe conditions, capitalize on the growing CBD skincare market which is estimated to be worth USD 1295.7 Million by 2026 and is foreseen to garner a CAGR of about 33% from 2021 to 2026.
Keeping with their 2022 mission of creating purposeful formulations, Panacea is not only looking to use cannabinoids to help treat ailments from the inside of the body – some of their most recent product launches are aimed at addressing topical conditions that millions of people face. In America alone, the numbers are staggering.
| Condition | Acne | Atopic Dermatitis/ Eczema | Psoriasis | Rosacea |
|---|---|---|---|---|
| # of Americans Affected | Up to 50 Million (annually)1 | 31.6 Million2-3 |
7.5 Million4 | 16 Million5-7 |
Increased adoption of skincare products containing CBD and/or CBG is driving growth throughout the industry. Panacea’s skincare line is dermatologist-approved and packed with anti-inflammatory properties and free-radical-fighting antioxidants. The all-natural formulations include ingredients like targeted peptides, vitamins, green tea, aloe, Beta Hydroxy Acid, tea tree oils, and more, and of course, CBD and CBG to help address skin ailments and to protect the skin from harmful pollutants and free radical damage.
Knowing that the market is looking for natural products with clean ingredients and free of parabens, sulfates or animal testing, Panacea has been working closely with certified dermatologist Dr. Paul Dean, partner of PL Skin Solutions based in California, to go above and beyond consumer demand by offering products made with all-natural ingredients, including hemp-derived CBD and CBG that is organically grown and manufactured in the U.S., and ensuring they are third-party tested and dermatologist approved.
“I am thrilled to be part of Panacea’s superior skincare line. I have assisted in the formulation of these unique skincare products which have a blend of antioxidants and CBD and CBG ingredients. It’s amazing to see how my patients have benefited significantly from the use of these products” says Dr. Dean.
Panacea’s four new CBD skincare products cover much of the overall skincare market by type, providing serums, lotions, gels, and creams, but the additional Derma Soothe CBD+CBG Skin Relief product differentiates their line by addressing more severe skin conditions like rosacea, eczema, and even psoriasis.
The relatively new baseline of products can either be used together as a four-part skin regimen or on their own. Products include a CBD Soothing Eye Therapy serum, CBD Regenerating Facial Cream, Skin Clearing CBD Gel, and a Full Body CBD Moisture Therapy lotion. However, if the goal is to tackle more severe or widespread skin conditions, the Derma Soothe CBD+CBG Skin Relief is a must.
Nick Cavarra, Panacea’s Executive Vice President of Sales and Marketing, states, “Panacea customers have wanted us to create a premier line of CBD and CBG skincare products, and our R&D team along with Dr. Dean have accomplished this by working closely together over the last year on formulation, stability, and efficacy of the products. Panacea is pleased to offer our skincare products to the marketplace and believe they will differentiate us from our competition by delivering purposeful products to our customers desperate for a natural solution to their afflictions.”
Since their founding in 2017, Panacea Life Sciences has upheld the highest standards for all their products across multiple categories, from oil drops and softgels to gummies and topicals. With a focus on Cultivating Everyday Wellness™ by making purposeful products that use only the highest quality cannabinoids, the brand continues to build trust and reliability with each new product in its lineup.
Beginning today through Monday, March 7th, Panacea is running a Skincare Special. When you purchase the Skincare Bundle (which includes the CBD Soothing Eye Therapy serum, CBD Regenerating Facial Cream, and the Full Body CBD Moisture Therapy lotion), use the coupon code SKINCARE at checkout to receive a free, full-sized Skin Clearing CBD Gel.
About Panacea Life Sciences Holdings, Inc.
Panacea Life Sciences Holdings, Inc. is a woman-owned, vertically integrated cannabinoid manufacturer and research company that produces purposeful formulations for consumers and pets. Panacea sells an array of products including softgels, gummies, tinctures, sublingual tablets, skin care, and pain management topicals. If you would like more information about this topic or to learn more about Panacea and its products or our land-to-brand practices, please visit www.panacealife.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our CBD and CBG skincare products, including the perceived merits and anticipated outcome of our products, consumer demand for and suitability of our products in retail locations and in general, and the expected growth of the CBD/hemp industry in which we operate. You can identify forward-looking statements by use of the words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the possibility that our Pana skincare products are not successful, risks arising from supply chain disruptions on our ability to obtain raw materials as well as similar problems with our vendors, the impact of the pandemic including new variants on the national and global economy, lack of available funding at sufficient levels to meet our working capital needs, competition from third parties; intellectual property rights of third parties; regulatory constraints, including the need for FDA approval under certain circumstances; and changes in technology and methods of marketing; as well as those risks and uncertainties described by us in our quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2021 under the heading “Risk Factors”. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law.
Contact:
Nick Cavarra
[email protected]
